



Program Name:	St. Jude-VIVA Survivorship Series 3 Webinar #2
<b>Event Date:</b>	15 December 2023, Friday
<b>Event Time:</b>	9.00pm - 10.30pm (Singapore Time)

## **Programme Synopsis**

## **Lecture Title:**

## Anticipating Long-Term Health Outcomes of Therapy of NHL

Dr Matthew Ehrhardt, St Jude Children's Research Hospital

Greater than 90% of children newly diagnosed with non-Hodgkin lymphoma (NHL) in high-income countries are expected to experience long-term survival. Despite these excellent outcomes, long-term survivors of childhood NHL experience morbidity and mortality related to prior cancer treatments, highlighting the importance of strategies to mitigate late toxicity. Effective treatment regimens for pediatric NHL have evolved to reduce both short-and long-term toxicity and thus facilitate opportunities for shared decision-making regarding frontline treatment selection that considers efficacy, acute toxicity, convenience, and late effects of treatments. The current presentation seeks to enhance understanding of potential long-term health risks to facilitate decision-making for children diagnosed with NHL.





**Presenter Bio** 

**Dr Matthew Ehrhardt** 

Cancer Survivorship, Leukemia / Lymphoma Division, Comprehensive Cancer Center Assistant Member, St. Jude Faculty St. Jude Children's Research Hospital USA

Dr. Matthew Ehrhardt is an Associate Member in the Division of Cancer Survivorship at St. Jude Children's Research Hospital. Dr. Ehrhardt received his medical degree from the University of Illinois College of Medicine at Peoria and completed training in pediatrics, internal medicine, and pediatric hematology/oncology/blood and marrow transplantation at the Medical College of Wisconsin. He completed an additional year of training in childhood cancer survivorship at St. Jude Children's Research Hospital, where he currently specializes in the care of children newly diagnosed with Hodgkin and non-Hodgkin lymphomas and long-term childhood cancer survivors. Dr. Ehrhardt's clinical research is focused on the long-term effects of childhood cancer treatment and surveillance guideline development, dissemination, and utilization. He is currently Co-Chair of the Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers and an active participant in the International Guideline Harmonization Group for Late Effects of Childhood Cancer.



**Organising Chair/Moderator** 

**Dr Melissa Hudson** 

Member, St. Jude Faculty
Director, Cancer Survivorship Division
Co-Leader, Cancer Control & Survivorship Program
The Charles E. Williams Endowed Chair of Oncology-Cancer
Survivorship
St. Jude Children's Research Hospital
USA